Fig. 2

Analysis of GSK3 substrate regulation in lymphoma cells: HS-Sultan (A), Karpas-299 (B), and HH (C) cells were exposed to the compounds for 4 h prior to cell lysis and western blotting for the GSK3 substrates β-catenin and phospho-CRMP2, using b-actin and total CRMP2 as loading controls. D IC₅₀ determination (0.37 µM) in an in vitro GSK3β assay. E Comparison of reported IC₅₀ measures for the GSK3 inhibitors used in this study. F The 22 kinases which were inhibited more than 50% by 5 µM elraglusib in a cell-free kinase screen (100 kinases) performed within the MRC PPU at the University of Dundee. Available published data for CT99021 and SB216763 are given as comparison against these kinases in the same assay conditions. Data are ‘remaining kinase activity’ relative to DMSO carrier control and are the average of triplicate assays